MXPA05011038A - Hidrogenacion de compuestos intermedios de imina de sertralina con catalizadores. - Google Patents

Hidrogenacion de compuestos intermedios de imina de sertralina con catalizadores.

Info

Publication number
MXPA05011038A
MXPA05011038A MXPA05011038A MXPA05011038A MXPA05011038A MX PA05011038 A MXPA05011038 A MX PA05011038A MX PA05011038 A MXPA05011038 A MX PA05011038A MX PA05011038 A MXPA05011038 A MX PA05011038A MX PA05011038 A MXPA05011038 A MX PA05011038A
Authority
MX
Mexico
Prior art keywords
catalysts
sertraline
hydrogenation
imine intermediates
intermediates
Prior art date
Application number
MXPA05011038A
Other languages
English (en)
Inventor
Mark Kalya
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of MXPA05011038A publication Critical patent/MXPA05011038A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/44—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of carboxylic acids or esters thereof in presence of ammonia or amines, or by reduction of nitriles, carboxylic acid amides, imines or imino-ethers
    • C07C209/52—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of carboxylic acids or esters thereof in presence of ammonia or amines, or by reduction of nitriles, carboxylic acid amides, imines or imino-ethers by reduction of imines or imino-ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/70—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of the iron group metals or copper
    • B01J23/74—Iron group metals
    • B01J23/75—Cobalt
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J35/00—Catalysts, in general, characterised by their form or physical properties
    • B01J35/60—Catalysts, in general, characterised by their form or physical properties characterised by their surface properties or porosity
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J35/00—Catalysts, in general, characterised by their form or physical properties
    • B01J35/60—Catalysts, in general, characterised by their form or physical properties characterised by their surface properties or porosity
    • B01J35/61—Surface area
    • B01J35/613—10-100 m2/g
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J35/00—Catalysts, in general, characterised by their form or physical properties
    • B01J35/60—Catalysts, in general, characterised by their form or physical properties characterised by their surface properties or porosity
    • B01J35/64—Pore diameter
    • B01J35/647—2-50 nm

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se proporcionan proceso de hidrogenacion de compuestos intermedios de imina de sertralina con catalizadores en diferentes reactores.
MXPA05011038A 2003-04-14 2004-04-14 Hidrogenacion de compuestos intermedios de imina de sertralina con catalizadores. MXPA05011038A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46281603P 2003-04-14 2003-04-14
PCT/US2004/011634 WO2004092110A2 (en) 2003-04-14 2004-04-14 Hydrogenation of imine intermediates of sertraline with catalysts

Publications (1)

Publication Number Publication Date
MXPA05011038A true MXPA05011038A (es) 2006-01-24

Family

ID=33299994

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05011038A MXPA05011038A (es) 2003-04-14 2004-04-14 Hidrogenacion de compuestos intermedios de imina de sertralina con catalizadores.

Country Status (8)

Country Link
US (3) US7276629B2 (es)
EP (1) EP1583734A2 (es)
CA (1) CA2522534A1 (es)
DE (1) DE04750154T1 (es)
ES (1) ES2242555T1 (es)
MX (1) MXPA05011038A (es)
TW (1) TW200503991A (es)
WO (1) WO2004092110A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200503991A (en) * 2003-04-14 2005-02-01 Teva Pharma Hydrogenation of imine intermediates of sertraline with catalysts
US7262327B2 (en) * 2003-09-05 2007-08-28 Teva Pharmaceutical Industries Ltd. Recycling process for preparing sertraline
WO2006072878A1 (en) * 2005-01-07 2006-07-13 Ranbaxy Laboratories Limited Oral dosage forms of sertraline having controlled particle size and processes for their preparation
TW200640836A (en) * 2005-02-23 2006-12-01 Teva Pharma Processes for preparing sertraline
WO2008071640A2 (en) * 2006-12-12 2008-06-19 Shell Internationale Research Maatschappij B.V. Process for preparing a catalyst
WO2010076763A2 (en) * 2009-01-02 2010-07-08 Piramal Healthcare Limited An improved process for the manufacture of sertraline
US8233987B2 (en) 2009-09-10 2012-07-31 Respicardia, Inc. Respiratory rectification

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2486361A (en) * 1944-10-20 1949-10-25 Union Oil Co Catalytic conversion of hydrocarbons
US3274124A (en) * 1964-01-02 1966-09-20 Universal Oil Prod Co Process of preparing a silica-alumina supported group viii metal hydrocracking catalyst
JPS5439349B1 (es) * 1971-06-08 1979-11-27
US3926842A (en) * 1973-01-02 1975-12-16 Texaco Inc Method of regenerating spent hydroalkylation catalyst containing an oxidizable group viii metal
FR2398540A1 (fr) * 1977-07-29 1979-02-23 Raffinage Cie Francaise Procede de preparation d'alumines a porosite controlee et applications des alumines ainsi preparees
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
GB9114948D0 (en) * 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5252613A (en) * 1992-12-18 1993-10-12 Exxon Research & Engineering Company Enhanced catalyst mixing in slurry bubble columns (OP-3723)
HU222341B1 (hu) 1996-12-18 2003-06-28 Richter Gedeon Vegyészeti Gyár Rt. Eljárás sertralin előállítására és az eljárásban alkalmazott intermedier
US5939350A (en) * 1997-02-10 1999-08-17 Energy International Corporation Processes and catalysts for conducting fischer-tropsch synthesis in a slurry bubble column reactor
WO1999047486A1 (en) * 1998-03-18 1999-09-23 Ciba Specialty Chemicals Holding Inc. Process for the cis-selective catalytic hydrogenation of cyclohexylidenamines
HU226424B1 (en) * 1998-05-05 2008-12-29 Egis Gyogyszergyar Nyrt Process for producing enantiomer mixture for preparation of sertraline
WO2000025598A1 (en) * 1998-11-03 2000-05-11 Dandy A/S Sucrose fatty acid esters for use as increased release of active ingredients
US6262132B1 (en) * 1999-05-21 2001-07-17 Energy International Corporation Reducing fischer-tropsch catalyst attrition losses in high agitation reaction systems
US6593496B1 (en) * 1999-06-09 2003-07-15 Pfizer Inc Process for preparing sertraline from chiral tetralone
WO2001009080A1 (en) * 1999-07-29 2001-02-08 Ciba Specialty Chemicals Holding Inc. Process for the cis-selective catalytic hydrogenation of cyclohexylidenamines
IN185109B (es) 1999-09-01 2000-11-18 Torrent Pharmaceuticals Ltd
IN187170B (es) * 2000-01-04 2002-02-23 Sun Pharmaceutical Ind Ltd
JP2003527359A (ja) * 2000-03-14 2003-09-16 テバ ファーマシューティカル インダストリーズ リミティド （＋）−シス−セルトラリンの製造のための新規方法
EP1401800A1 (en) * 2001-06-15 2004-03-31 Orion Corporation Fermion A novel process for the preparation of (is-cis) -4-(3, 4-dichlorophenyl) -1, 2, 3, 4 - tetrahydro-n-methyl-1-naphthalenamine
US6683220B2 (en) 2001-10-31 2004-01-27 Pfizer, Inc. Process for the preparation of optically pure or enriched racemic tetralone
TW200503991A (en) * 2003-04-14 2005-02-01 Teva Pharma Hydrogenation of imine intermediates of sertraline with catalysts

Also Published As

Publication number Publication date
ES2242555T1 (es) 2005-11-16
DE04750154T1 (de) 2005-12-29
US20080207439A1 (en) 2008-08-28
TW200503991A (en) 2005-02-01
EP1583734A2 (en) 2005-10-12
US20080004351A1 (en) 2008-01-03
WO2004092110A3 (en) 2005-06-09
CA2522534A1 (en) 2004-10-28
WO2004092110A2 (en) 2004-10-28
WO2004092110B1 (en) 2005-09-01
US7276629B2 (en) 2007-10-02
US20050085669A1 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
AU2002353035A1 (en) Advances in amination catalysis
DE60330752D1 (de) Regenerierung von katalysatoren für die hydrierung von kohlenstoffmonoxid
WO2004046102A3 (en) Novel graphite nanocatalysts
ZA200707894B (en) High conversion hydroprocessing using multiple pressure and reaction zones
MX2007007302A (es) Proceso para la preparacion de clorhidrato de 1-amino-3,5-dimetiladamantano.
TNSN08103A1 (en) Treatment of autoimmune diseases
GB2388056B (en) Synthesis of polyisoprene with neodymium catalyst
MX2007005936A (es) Una sintesis asimetrica del acido (s)-(+)-3-(aminometil)-5- metilhexanoico.
ZA200700453B (en) High-activity isomerization catalyst and process
TW200604149A (en) Norbornane based cycloaliphatic compounds containing nitrile groups
CA2558194A1 (en) Hydrogenation of acetone
TW200637806A (en) 2-alkylcycloalk(en)ylcarboxamides
TW200503991A (en) Hydrogenation of imine intermediates of sertraline with catalysts
ATE554061T1 (de) Verfahren zur herstellung von aminen
EP1702681A3 (de) Katalysatorformkörper, insbesondere zur Verwendung als Katalysatoren bei der Hydrierung
BRPI0308119A2 (pt) microorganismo como portadores de seqüências de nucleotídeos codificando para antígenos de células para o tratamento de tumores.
SG146640A1 (en) Isolated photoprotein mtclytin, and use thereof
BRPI0407714A (pt) "exo-2r (+)-2-amino-7-azabiciclo[2.2.1]heptano-7-carboxilato de t-butila, intermediário, e processo para os preparar e isolar
TW200708620A (en) Anoxic ammonia oxidation system with an immobilized bioreactor
TW200640836A (en) Processes for preparing sertraline
CA114997S (en) Faucet
TW200724231A (en) Meal catalyst and hydrogenation of unsaturated polymer and nitrile-butadiene rubber employing the same
TW200420539A (en) Hydrogenation process
BRPI0411263A (pt) processo para a preparação de 2-(aminometil)-1-ciclopentilamina
PL377901A1 (pl) Katalizatory uwodorniania